Little is known about the role of acute GvHD (aGvHD) based on the concept of graft-versus-leukaemia effect (GVLE) after unrelated donor haematopoietic stem cell transplantation (uHSCT). We evaluated 67 uHSCTs performed with multinational unrelated donors for patients with AML. The median follow-up duration was 18 months (range 7-61). The majority of patients had intermediate-or high-risk cytogenetic findings. The conditioning regimen for most patients consisted of cyclophosphamide plus total body irradiation (n ¼ 56) with our standard GvHD prophylaxis containing tacrolimus plus a short course of methotrexate. The incidence of aGvHD and chronic GvHD was 50 and 52%, respectively. Eight patients (12%) have relapsed to date. The estimated overall disease-free survival (DFS) rate at 5 years was 67%. Notably fewer relapses were seen when aGvHD developed (P ¼ 0.008). Specifically, high-risk AML patients had a much lower relapse rate when they developed aGvHD (P ¼ 0.01), compared with the intermediate-risk group. Therefore, the development of aGvHD after uHSCT in AML patients is closely related to a lower relapse rate, probably in association with GVLE.
Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT) with sibling or unrelated donors is currently the best therapy for high-risk AML. 1, 2 Although the outcome of transplants from HLA-matched unrelated donors on the basis of high-resolution typing is comparable to those of HLA-identical sibling transplants, GvHD has remained a significant problem in patients after either related or unrelated donor HSCT, in addition to the serial incidence of relapse in each setting. [3] [4] [5] [6] With the establishment of several registries for unrelated volunteer donors in Japan, Taiwan and Korea, and with the availability of more precise tissue typing technology, we can now more clearly differentiate matched from mismatched unrelated donors. Currently, many AML patients without HLAmatched siblings have received transplants from unrelated donors. 7, 8 Concerning the graft-versus-leukaemia effect (GVLE), chronic GvHD (cGvHD) after allogeneic HSCT has been strongly associated with a lower relapse rate of AML in many older reports. [9] [10] [11] However, there is no direct evidence that acute GvHD (aGvHD) after related or even unrelated donor HSCT (uHSCT) is beneficial to the long-term disease-free survival (DFS) of AML patients, in terms of enhancing the GVLE. Interestingly, we noted a much lower relapse rate in patients who developed mild to moderate aGvHD after uHSCT, compared with patients who did not.
We performed uHSCT using Korean, Japanese, Taiwanese and Caucasian donors in intermediate-and high-risk AML patients who had no suitable HLAmatched related donors. We retrospectively reviewed all medical records of uHSCTs performed in our transplant centre since the year 2001. We investigated the outcome of uHSCT in Korean patients with AML who had a high post-transplant risk for aGvHD and other transplantrelated complications (TRCs). The risks were based on HLA allele(s) or antigen matches or mismatches with regard to patient and donor matching status. Our results show that transplants from multinational unrelated donors, which were expected to have many incompatible minor histocompatibility antigens compared with those from either matched or mismatched siblings, can result in successful long-term DFS with tolerable GvHD and other TRCs.
Patients and methods

Patient characteristics
Sixty-seven consecutive adult AML patients with a variety of clinical findings underwent transplantation at the Catholic Haemopoietic Stem Cell Transplantation Centre of Korea from December 2001 with follow-up through mid-December 2006. We screened all patients and donors for HLA-A, -B, -Cw and -DRB1 alleles using a highresolution (DNA sequencing) molecular typing method. According to our policy for locating unrelated donors, we began with a search of the domestic donor registries; if no match was found, we then searched the Asian donor registries (Japan and Taiwan); if we still found no match, we then searched the American (National Marrow Donor Program, NMDP) and European (Zentrales Knochenmarkspender-Register Deutschland, ZKRD) donor registries. The median time to transplantation from CR was 6 months (range 4-10). All patients undergoing post-transplant follow-up were included in the long-term follow-up analysis (Table 1) .
Cytogenetic risk groups were classified using the guidelines of the SWOG trial. 12 Briefly, patients with normal karyotypes in addition to þ 8, -Y, þ 6 and del(12p) identified at presentation were considered to be at intermediate risk (n ¼ 43). Excepting t(15;17) or inv(16)/t(16;16)/ del(16q) being present with any other abnormality, and t(8;21) without del(9q), all other specific cytogenetic abnormalities were deemed unfavourable (n ¼ 24).
Induction and consolidation chemotherapy
All patients were treated according to our standard protocol, which consists of a 3 Â 7 idarubicin (IDA) plus N4-behenoyl-1-b-D-arabinofuranosyl cytosine (BH-AC) induction chemotherapy. Briefly, IDA was administered daily at a dose of 12 mg/m 2 for 30 min intravenously for three consecutive days, and BH-AC was administered daily at a dose of 300 mg/m 2 over a period of 4 h for 7 consecutive days, as previously reported. 13 For all AML patients enrolled in this study, we used the same induction and consolidation strategy. This consolidation chemotherapy was repeated for one to two courses according to the search results for a donor and the clinical condition of the patient. The first consolidation chemotherapy consisted of a combination of BH-AC (300 mg/m 2 intravenously for 5 days) and IDA (12 mg/m 2 intravenously for 3 days; n ¼ 47). For the patients who needed a second consolidation block, a combination of mitoxantrone (12 mg/m 2 intravenously for 3 days) and etoposide (100 mg/m 2 intravenously for 5 days; n ¼ 11) was provided. Due to the delay in her transplant schedule, one patient received a third consolidation block consisting of a combination of amsacrine (100 mg/m 2 intravenously for 3 days) and cytosine arabinoside (1.0 g/m 2 b.i.d. intravenously for 5 days).
Transplants from unrelated donors
Overall, 53 patients received unrelated donor BM cells, whether or not they were in CR. Fourteen patients received G-CSF-mobilized PBSC because there was a weight discrepancy of more than 10 kg between the donor and recipient or because the donor refused to have BM retrieval performed under general anaesthesia. Among the PBSC donors, all were from the domestic registries, except for four cases from Taiwan and the United States. The median number of infused CD34 þ cells was 4.2 Â 10 6 cells/kg Between December 2005 and November 2006, we studied the addition of antithymocyte globulin (ATG; thymoglobulin, SangStat, Lyon, France (now Genzyme, Cambridge, MA, USA)), at a dose of 1.25 mg/kg of body weight per day on days -3 and -2 for recipients who received PBSC from mismatched unrelated donors (n ¼ 12); this was added to prevent the development of aGvHD, together with our standard regimen of methotrexate (10 mg/m 2 intravenously as a bolus on day þ 1, and methotrexate 5 mg/m 2 intravenously as a bolus, on days þ 3, þ 6 and þ 11) and tacrolimus starting at day -1. This particularly low-dose ATG protocol was based on reports that showed the development of manageable GvHD at a total dose range of 4.5-15 mg/kg. 14, 15 In the absence of aGvHD, tacrolimus was tapered by 25% biweekly, beginning on day 120 post transplantation. In some patients (n ¼ 2), methotrexate was not administered on day þ 11 if the status of the patient did not warrant it, such as in cases of severe mucositis. G-CSF was administered to all patients at a dose of 5 mg/kg per day subcutaneously from day þ 7 after transplantation until neutrophil recovery.
Time to haematopoietic recovery was defined as an ANC X0.5 Â 10 9 cells/l and a platelet count X20 Â 10 9 cells/l, with no platelet transfusion needed for 3 consecutive days. Engraftment was assessed by analysing a routine marrow aspirate at day þ 21. Graft failure or aplasia was defined as the absence of haematological recovery until day þ 28 in patients after transplantation. Toxicity grading was assessed using the WHO criteria. 16 All patients received prophylactic antibiotics starting from day -14 until an ANC of 1.5 Â 10 9 cells/l was achieved. All patients received anti-fungal prophylaxis with itraconazole from day -14 to þ 60 post transplant. Pneumocystis carinii pneumonia (PCP) prophylaxis with co-trimoxazole (Bactrim, Roche, Basel, Switzerland) was given throughout conditioning, discontinued 48 h before stem cell infusion, and then given from day þ 21 to þ 90. Blood components given to patients were irradiated and leukocyte filtered before transfusion.
Statistical analysis DFS was calculated from the date of transplantation until the date of relapse or death from any cause, or the date of last follow-up for patients who were alive and in CR. Time to relapse (TR) was calculated from the date of transplantation until the date of relapse. The probability of relapse was estimated using the cumulative incidence method. Cumulative incidence of relapse was defined based on morphological evidence of leukaemia in BM or extramedullary organs. To evaluate the probability of relapse, we censored patients who died from either direct procedural toxicity or any other cause not related to leukaemia. Overall survival (OS) was calculated from the time of diagnosis to death. The Kaplan-Meier method was used to calculate DFS, OS and the probability of relapse; the statistical significance of the differences under various clinical conditions was calculated using the log-rank test. Patients still alive and in CR were censored at their last follow-up. Univariate analysis was performed to test for associations between clinical outcome and the demographic profiles of recipients and donors, disease status before transplantation, clinical variables, presence or absence of aGvHD and cGvHD and stem cell source (domestic vs foreign donor) by using the Cochran-Mantel-Haenszel test. Factors associated with each clinical parameter at Po0.20 in the univariate analyses were then used in the multivariate Cox's proportional hazards regression analysis, using a forward stepwise approach. For all analyses, Po0.05 was considered statistically significant. The last follow-up date was 15 December 2006.
Results
Engraftment
We experienced only a single case (1.5%) of graft failure. That patient had received stem cells from a Korean donor and an infused cell dose of 2.1 Â 10 6 cells/kg CD34 þ cells. Fortunately, the patient recovered with an autologous PBSC infusion after 4 weeks of marrow aplasia. Interestingly, one patient, who had received 0.2 Â 10 6 cells/kg CD34 þ BM cells from a Japanese donor, recovered without any further support with stem cells and has remained in excellent clinical condition. Overall, sustained neutrophil and platelet engraftment was obtained at a median of 17 days (range 12-24) and 19 days (range 15-23), respectively, after transplantation for all of the patients evaluated.
Survival rate
The overall 5-year estimated DFS and OS rates for uHSCT using multinational donor registries were 67 and 68%, respectively ( Figure 1) . We analysed the overall survival rates based on the development of aGvHD or cGvHD, after selecting donors with HLA-matches or mismatches; however, only patients with aGvHD who had received transplants from HLA-matched unrelated donors showed a statistically significant difference in DFS using the log-rank test (P ¼ 0.03). As expected, the pre-uHSCT status of the patients, that is, whether they were CR or IR/refractory, was significantly associated with DFS (Table 2) .
Relapse associated with GvHD
We compared the probability of relapse curves according to the presence or absence of aGvHD or cGvHD. Eight patients relapsed. Of the nine patients who were in IR or a refractory status pre-transplant, three relapsed early after transplantation (33%). The other five patients who relapsed were in the CR group (58 patients) pre transplant (9% Figure 2a . Relapse rate decreased when aGvHD was present. cGvHD developed in 52% (27/52) of the evaluated patients; 17% of them (9/52) had extensive disease. Among these, aGvHD progressed to a chronic form (progressive type) in 56% (15/27) of the patients. When we compared the incidence of GvHD between the HLA-matched group (n ¼ 37) and HLAmismatched group (n ¼ 30), the rates of aGvHD and cGvHD for the two groups were 59 vs 34% and 50 vs 50%, respectively. By contrast, the development of cGvHD did not influence relapse rates, as shown in Figure 2b . NS  ---NS  ---HLA match, with or without aGvHD  NS  ---NS  ---HLA mismatch, with or without aGvHD  NS  ---NS  ---HLA match, with or without cGvHD  NS  ---NS  ---HLA Patients categorized cytogenetically as high risk had much lower relapse rates when they specifically developed aGvHD, compared with the intermediate-risk group (Figures 3a and b) . Combining all of the data, we evaluated whether the development of aGvHD or cGvHD after uHSCT affected clinical outcome by using multivariate Cox's proportional hazards regression analysis. The development of aGvHD and the severity of aGvHD were closely associated with a lower relapse rate, whereas cGvHD was not ( Table 2 ). The pre-uHSCT status of the patient was also significantly associated with relapse. These findings suggest that aGvHD following uHSCT in AML patients has anti-leukaemic effects.
Transplant-related mortality
The cumulative incidence of non-relapse transplant-related mortality (TRM) was 16% (11/67). Six of the 11 died from pneumonia. Three patients had severe veno-occlusive disease combined with pneumonia. Two other patients died from either the progression of an extensive type of cGvHD or thrombotic thrombocytopenic purpura. Most of the diagnoses were confirmed by the appropriate laboratory tests, except for a case suspicious of PCP (n ¼ 1) with unexplained alveolar haemorrhages. Of the 67 patients, 5 (7%) died within the first 100 days following uHSCT, and 6 (9%) died more than 100 days after uHSCT.
Discussion
Prior reports have confirmed that GvHD is the most important independent factor associated with a decreased relapse rate due to GVLE. 17, 18 However, the clinical findings associated with GvHD are not the only factors important for a GVLE. It is possible to induce GVLE independently of GvHD. 11 The role of aGvHD or cGvHD based on the above concept of GVLE in patients has not been well defined in patients with high-risk AML in CR or IR after uHSCT; this is particularly true for aGvHD in the setting of uHSCT, and may be attributable to the differences in clinical protocols among different transplant centres. In addition, the evaluation of marrow versus peripheral blood as a stem cell source should be a major factor examined to determine post-transplant complications, in addition to the development of aGvHD or cGvHD.
The development of aGvHD after uHSCT in AML patients was closely related to a lower relapse rate (Table 2 and Figure 2 ). This finding was further supported by the results seen in the group of high-risk patients (Figure 3 ). These findings suggest that aGvHD has a unique role in uHSCT, compared to the reported role of cGvHD, related to an anti-leukaemic GVLE. Although the mechanism involved in this phenomenon is uncertain, both aGvHDrelated cytokines and the activation of anti-leukaemic cytotoxic T cells, specifically in relation to minor histocompatibility antigen disparities in uHSCT, might be reinforced more vigorously from the early period of transplant. In particular, the relatively lower incidence and milder cases of aGvHD related to the positive effect on lower relapse in the group of patients who received uHSCT from HLA-mismatched donors may have resulted from the use of ATG in some of the patients. Similar to the results in other reports, 14, 15 we experienced manageable aGvHD in all cases, without any negative effects on relapse, in this group of patients. Therefore, we expect that future studies with larger samples will reveal the role of ATG in the context of GvHD vs GVLE in populations with a similar risk for AML.
After uHSCT using multinational donors, Korean intermediate-to high-risk AML patients had a 67% overall 5-year estimated DFS, suggesting that uHSCT from worldwide registries is a useful treatment option. If we could improve on the TRM, uHSCT using multinational registries might be more desirable than other transplant options such as umbilical cord blood or high-grade HLAmismatch HSCT. Our results suggest that worldwide multinational registries are useful for intermediate-to high-risk AML patients who require HSCT but have no matched family or national donor available. Although additional studies are now needed with larger study populations and longer follow-up to confirm our findings, our results suggest that the development of aGvHD after uHSCT in high-risk AML patients is closely related to a lower relapse rate, probably in association with a GVLE. 
